News

Q Chip, a biopharmaceutical drug delivery company, is developing a range of sustained-release biosimilars using its patented Q-Sphera bioencapsulation platform. Q-Sphera is an enabling technology for peptide and

“We are very excited about this agreement as it will launch us into the worldwide bovine tuberculosis testing market. This affliction costs the worldwide cattle industry billions of

DATATRAK International has announced the signing of two studies exemplifying the versatility of the DATATRAK eClinical platform. The first is a six-year, 400-patient registry study being conducted by

Nutra Pharma plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in

Helsinn has provided new positive data presented at the ECCO-ESMO joint European oncology conference in Berlin, for palonosetron. Palonosetron, a second generation 5-HT3 receptor antagonist, which improves emesis

BioMarin Pharmaceutical has initiated treatment in the phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). The initial top-line results

OrbusNeich’s interim data from a prospective registry showed good safety in a broad population of patients that underwent primary percutaneous coronary intervention (PCI) and implantation of the company’s

Genomic Health has declared results from the first study to compare the distribution of Oncotype DX Recurrence Score results between European, Middle Eastern and the US patient populations.

Amgen has detailed its results from a phase 3, head-to-head trial evaluating denosumab versus Zometa in the treatment of bone metastases. The trial was conducted in 2,046 patients